Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 1/20 | 0.34 |
| ▸ | MET | P08581 | 2/20 | 0.33 |
| ▸ | CCR3 | P51677 | 1/20 | 0.32 |
| ▸ | EP300 | Q09472 | 1/20 | 0.32 |
| ▸ | RORC | P51449 | 1/20 | 0.32 |
| ▸ | FPR2 | P25090 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15205485 | 1.00 | CNR2 (0.34) | CNR2METCCR3EP300RORC | |
| SCHEMBL15206181 | 0.93 | MET (0.35) | METFPR2 | |
| SCHEMBL15206179 | 0.93 | MET (0.35) | METFPR2 | |
| SCHEMBL15206023 | 0.80 | ACACB (0.33) | MET | |
| SCHEMBL15206021 | 0.80 | ACACB (0.33) | MET | |
| SCHEMBL15205284 | 0.80 | IRAK4 (0.35) | MET | |
| SCHEMBL15205282 | 0.80 | IRAK4 (0.35) | MET | |
| SCHEMBL15205488 | 0.78 | CCNT1 (0.38) | MET | |
| SCHEMBL15205490 | 0.78 | CCNT1 (0.38) | MET | |
| SCHEMBL15206212 | 0.76 | CHRM2 (0.38) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130225548-A1 | Pyridine Derivative and Medicinal Agent | NIPPON SHINYAKU CO., LTD. (JP) | 2013-08-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130225548-A1 | Pyridine Derivative and Medicinal Agent | NR0B2, NR0B1, CNKSR1 | CNR2 82/4885MET 162/4885CCR3 736/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.